

In re Application of: Weiniu GAN et al.

Art Unit: 1634

Serial No.: 09/805,455

Examiner: J. Fredman

Filed: March 14, 2001

Atty. Docket: CL001165

For: ISOLATED HUMAN RAS-LIKE PROTEINS, NUCLEIC ACID MOLECULES ENCODING THESE HUMAN RAS-LIKE PROTEINS, AND

USES THEREOF

RESPONSE TO FINAL OFFICE ACTION

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231 Mail Stop AF

Sir:

This is in response to an Office Action from Examiner Fredman mailed on March 20, 2003 for the above referenced application. Applicants request reconsideration of the above-referenced patent application in view of the following amendments and remarks.

Please amend the application as follows:

In the Claims:

Please amend claim 4 as follows:

- 4. (Twice Amended) An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of:
- (a) a cDNA sequence that encodes a protein comprising the amino acid sequence of SEQ ID NO:2;
 - (b) a nucleotide sequence consisting of SEQ ID NO:1;
 - (c) a nucleotide sequence consisting of SEQ ID NO:3; and
- (d) a nucleotide sequence that is completely complementary to a nucleotide sequence of (a)-(c).

Signature

12	JUN 1 0 2003	•	U.S. Pater	nt and T	PTO/SB/21 (03-03) Approved for use through 04/30/2003. OMB 0651-0031 rademark Office; U.S. DEPARTMENT OF COMMERCE	
$\overline{}$	Inser tha Papework Reduction Act of 1999	no person	s are required to respond to a collection Application Number	on of int	formation unless it displays a valid OMB control number.	
TRANSMITTAL FORM (to be used for all correspondence after initial filing)			Filing Date	March 14, 2001		
			First Named Inventor	Weiniu GAN		
			Art Unit	1634 /		
(to be used for all correspondence after fittual filling)			Examiner Name			
				J. Fredman		
Tota	al Number of Pages in This Submission		Attorney Docket Number	CLO	01165	
ENCLOSURES (Check all that apply)						
			Check all that	t appry	After Allowance Communication	
	Fee Transmittal Form	╎└─┤┆	Drawing(s)		to a Technology Center (TC)	
	Fee Attached	□	icensing-related Papers		Appeal Communication to Board of Appeals and Interferences	
~	Amendment/Reply	<u> </u> F	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
	After Final		Petition to Convert to a Provisional Application		Proprietary Information	
		 	Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer		Status Letter Other Enclosure(s) (please Identify below):	
	Affidavits/declaration(s)	lH °				
	Extension of Time Request	╎┼┤				
	Express Abandonment Request	Request for Refund			Cited References (5)	
~	Information Disclosure Statement		CD, Number of CD(s)			
	Certified Copy of Priority Document(s)	Remark	ks			
	Response to Missing Parts/ Incomplete Application					
	Response to Missing Parts					
	under 37 CFR 1.52 or 1.53					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm Justin D. Karjala, Registration No. 43,704						
or Individual						
Signature ()						
Date June 10, 2003						
CERTIFICATE OF TRANSMISSION/MAILING						
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:						
Typed or printed						

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Date